Literature DB >> 30040068

On Being a “Physician Patient” with His Own Experimental Therapeutic Drug

Rafiye Çiftçiler1, İbrahim C. Haznedaroğlu1.   

Abstract

Entities:  

Keywords:  Ankaferd; Burn; Physician patient; Mucosal healing

Mesh：

Substances：

Year:  2018        PMID： 30040068      PMCID： PMC6256832          DOI： 10.4274/tjh.2018.0254

Source DB:  PubMed          Journal:  Turk J Haematol        ISSN： 1300-7777            Impact factor:   1.831


× No keyword cloud information.
  5 in total

Review 1.  Pleiotropic cellular, hemostatic, and biological actions of Ankaferd hemostat.

Authors:  Berat Z Haznedaroglu; Yavuz Beyazit; Sharon L Walker; Ibrahim C Haznedaroglu
Journal:  Crit Rev Oncol Hematol       Date:  2011-11-12       Impact factor: 6.312

2.  The 1995 Albert Lasker Medical Research Award. Helicobacter pylori. The etiologic agent for peptic ulcer.

Authors:  B J Marshall
Journal:  JAMA       Date:  1995-10-04       Impact factor: 56.272

3.  Ankaferd blood stopper as a new strategy to avoid early complications after transradial procedures: A randomized clinical trial.

Authors:  Sevket Gorgulu; Tugrul Norgaz; Ilke Sipahi
Journal:  J Interv Cardiol       Date:  2018-04-17       Impact factor: 2.279

4.  Beneficial effects of Ankaferd Blood Stopper on dermal wound healing: an experimental study.

Authors:  Cagri Akalin; Serdar Kuru; Aziz Mutlu Barlas; Kemal Kismet; Bugra Kaptanoglu; Aydin Demir; Hesna Muzeyyen Astarci; Huseyin Ustun; Ertugrul Ertas
Journal:  Int Wound J       Date:  2012-09-03       Impact factor: 3.315

5.  Effectiveness of Ankaferd BloodStopper in Prophylaxis and Treatment of Oral Mucositis in Childhood Cancers Evaluated with Plasma Citrulline Levels.

Authors:  Türkan Patıroğlu; Nagihan Erdoğ Şahin; Ekrem Ünal; Mustafa Kendirci; Musa Karakükcü; Mehmet Akif Özdemir
Journal:  Turk J Haematol       Date:  2018-02-02       Impact factor: 1.831
  5 in total
  3 in total

1.  Effective Ankaferd Hemostat Treatment For Severe Intractable Chronic Deep Leg Ulcer Associated With Behçet's Disease.

Authors:  Rafiye Çiftçiler; Erdinç Çiftçiler; İbrahim Haznedaroğlu
Journal:  Arch Rheumatol       Date:  2019-04-26       Impact factor: 1.472

2.  Ankaferd hemostat (ABS) as a potential mucosal topical agent for the management of COVID-19 syndrome based on its PAR-1 inhibitory effect and oestrogen content.

Authors:  Fatma Beyazit; Yavuz Beyazit; Alpaslan Tanoglu; Ibrahim C Haznedaroglu
Journal:  Med Hypotheses       Date:  2020-07-31       Impact factor: 1.538

Review 3.  Pharmacobiological management of hemostasis within clinical backgrounds via Ankaferd hemostat (Ankaferd blood stopper).

Authors:  Rafiye Ciftciler; Ali Erdinc Ciftciler; Umit Yavuz Malkan; Ibrahim C Haznedaroglu
Journal:  SAGE Open Med       Date:  2020-02-16
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.